

PHAYM001: Preparation for professional practice

[View Online](#)

Antipsychotics increase mortality in elderly patients with dementia. (n.d.).
http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php

Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC). (n.d.).
<http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept>

Bhasin, M., Rowan, E., Edwards, K., & McKeith, I. (2007). Cholinesterase inhibitors in dementia with Lewy bodies—a comparative analysis. *International Journal of Geriatric Psychiatry*, 22(9), 890–895. <https://doi.org/10.1002/gps.1759>

British National Formulary. (n.d.). <http://www.bnf.org/bnf/index.htm>

Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University. (n.d.). <http://centrefor medicinesoptimisation.co.uk/mtrac/>

Chronic obstructive pulmonary disease. (n.d.).
<http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease>

Clinical guidelines, CG42 - Issued: November 2006. (n.d.). <http://guidance.nice.org.uk/CG42>

Coeliac disease: recognition, assessment and management | Guidance and guidelines | NICE. (n.d.). <https://www.nice.org.uk/guidance/ng20>

Commissioners and healthcare professionals - Training videos. (n.d.).
http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/

Complete Guide to Behavioural and Psychological symptoms of Dementia. (n.d.).
<http://www.ipa-online.org/>

CPPE - Centre for Pharmacy Postgraduate Education. (n.d.). <https://www.cppe.ac.uk/>

DH Living well with dementia: a National Dementia Strategy. (n.d.).
<https://www.gov.uk/government/organisations/department-of-health>

Ebixa 5mg/pump actuation oral solution, 20mg and 10 mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC). (n.d.).
<http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbixa+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/>

Electronic Medicines Compendium (eMC). (n.d.-a). <http://www.medicines.org.uk/emc/>

Electronic Medicines Compendium (eMC). (n.d.-b). <http://www.medicines.org.uk/emc/>

Electronic Medicines Compendium (eMC). (n.d.-c). <https://www.medicines.org.uk/emc/>

Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-a).
<https://www.evidence.nhs.uk/>

Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-b).
<https://www.evidence.nhs.uk/>

Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.-c).
<https://www.evidence.nhs.uk/>

Exelon - Summary of Product Characteristics (SPC) - (eMC). (n.d.).
<https://www.medicines.org.uk/emc/search?q=Exelon+>

GOV.UK. (n.d.). <https://www.gov.uk/government/organisations/department-of-health>

Greene, R. J., & Harris, N. D. (2008). Pathology and therapeutics for pharmacists: a basis for clinical pharmacy practice (3rd ed). Pharmaceutical Press.

Heart failure - chronic. (n.d.). <http://cks.nice.org.uk/heart-failure-chronic>

Hubley, J., Copeman, J., & Woodall, J. (2013). Practical health promotion (2nd ed). Polity Press.

Kavirajan, H., & Schneider, L. S. (2007). Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. *The Lancet Neurology*, 6(9), 782-792.
[https://doi.org/10.1016/S1474-4422\(07\)70195-3](https://doi.org/10.1016/S1474-4422(07)70195-3)

Kumar, P. J., & Clark, M. L. (2012). Kumar & Clark's clinical medicine (8th ed). Saunders Elsevier. <https://www.dawsonera.com/abstract/9780702053047>

Laverack, G. (2007). Health promotion practice: building empowered communities. Open University Press.
<https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=nlebk&AN=234222&site=ehost-live&scope=site&custid=s8454451>

Macdowall, W., Bonell, C., & Davies, M. (2006). Health promotion practice: Vol. Understanding public health. Open University Press.

Maher, A. R. (2011). Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic Review and Meta-analysis. *JAMA: The Journal of the American Medical Association*, 306(12).
<https://doi.org/10.1001/jama.2011.1360>

Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011). Efficacy and Comparative Effectiveness of Atypical

Antipsychotic Medications for Off-Label Uses in Adults. JAMA, 306(12).
<https://doi.org/10.1001/jama.2011.1360>

Map of Medicine | Home. (n.d.). <http://www.mapofmedicine.com/>

Martinón-Torres, G., Fioravanti, M., & Grimley Evans, J. (2004). Trazodone for agitation in dementia. Cochrane Database of Systematic Reviews.
<https://doi.org/10.1002/14651858.CD004990>

Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care. (n.d.). <https://www.evidence.nhs.uk/>

Medicines Use Review and Prescription Intervention service. (n.d.).
http://psnc.org.uk/wp-content/uploads/2013/06/MUR-service-spec-Aug-2013-changes_FINAL.pdf

Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: helping people change: Vol. Applications of motivational interviewing (3rd ed). Guilford Press.

National Institute for Health and Care Excellence. (n.d.). <http://www.nice.org.uk/>

NHS Health Check - NHS Choices. (n.d.).
<http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx>

NICE Clinical Knowledge Summaries (CKS). (n.d.). <http://cks.nice.org.uk/>

NPC | National Prescribing Centre. (n.d.-a). <https://www.guidelinesinpractice.co.uk>

NPC | National Prescribing Centre. (n.d.-b). <https://www.guidelinesinpractice.co.uk>

Optimising treatment and care for behavioural and psychological symptoms of dementia: A best practice guide. (n.d.). <https://www.alzheimers.org.uk/bpsdguide>

Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. (1998). Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia, 155(1), 54-61.
<https://doi.org/10.1176/ajp.155.1.54>

Prochaska, J. O., Norcross, J. C., & DiClemente, C. C. (1994). Changing for good. William Morrow.

Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC). (n.d.).

Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC). (n.d.).
<http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC>

Rollnick, S., Mason, P., & Butler, C. (1999). Health behavior change: a guide for practitioners. Churchill Livingstone.

Rollnick, S., Miller, W. R., & Butler, C. (2008). *Motivational interviewing in health care: helping patients change behavior: Vol. Applications of motivational interviewing*. Guilford Press.

Royal Pharmaceutical Society (RPS). (n.d.). <http://www.rpharms.com/home/home.asp>

Scottish Intercollegiate Guidelines Network (SIGN). (n.d.). <http://www.sign.ac.uk/>

Service specification - New Medicine Service (NMS). (n.d.).
http://psnc.org.uk/wp-content/uploads/2013/06/NMS-service-spec-Aug-2013-changes_FINAL.pdf

Sube Banerjee. (12 C.E.). *The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services*.
<http://psychrights.org/research/digest/nlps/BanerjeeReportOnGeriatricNeurolepticUse.pdf>
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (MS Word format). (n.d.).
<http://guidance.nice.org.uk/TA217/Guidance/doc/English>

Treatment protocol by NHS Medway: Treatment of Behaviour That Challenges. (n.d.).
<http://www.kmpt.nhs.uk/policies>

Waldemar, G., Hyvärinen, M., Josiassen, M. K., Kørner, A., Lehto, H., & Wetterberg, P. (2008). Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. *International Journal of Geriatric Psychiatry*, 23 (9), 979–981. <https://doi.org/10.1002/gps.1979>

Walker, R., & Whittlesea, C. (2012). *Clinical pharmacy and therapeutics* (5th ed). Churchill Livingstone.
<https://www.vlebooks.com/Product/Index/173020?page=0&startBookmarkId=-1>

Warner, J., & Smith, T. (n.d.). The rise and fall of antipsychotic prescribing in dementia. *Where do we go from here? The Rise and Fall of Antipsychotic Prescribing in Dementia*, 14 (2), 24–27.